Detalles de la búsqueda
1.
The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study.
Acta Oncol
; 57(1): 141-145, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29168668
2.
Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial.
Acta Oncol
; 57(1): 26-30, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29165021
3.
The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016.
Acta Oncol
; 57(1): 13-18, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29202621
4.
Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment.
Acta Oncol
; 55 Suppl 2: 24-35, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26797010
5.
Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
Acta Oncol
; 53(2): 174-85, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24219541
6.
Is DBCG abreast of new developments?
Acta Oncol
; 57(1): 1-2, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29297250
7.
Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.
Breast Cancer Res Treat
; 127(2): 345-55, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20556506
8.
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
NPJ Breast Cancer
; 6: 7, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140564
9.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
BMC Cancer
; 9: 185, 2009 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-19531212
10.
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Acta Oncol
; 48(4): 522-31, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19173092
11.
Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction.
Oral Oncol
; 44(2): 162-73, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17588802
12.
Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary.
Acta Oncol
; 47(4): 497-505, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465316
13.
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Acta Oncol
; 47(4): 662-71, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465334
14.
Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG Registry.
Acta Oncol
; 47(4): 525-36, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465318
15.
Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen Breast Cancer randomised study.
Acta Oncol
; 47(4): 633-8, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465331
16.
Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol.
Acta Oncol
; 47(4): 672-81, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465335
17.
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
Acta Oncol
; 47(4): 725-34, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465341
18.
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise.
Acta Oncol
; 47(4): 506-24, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465317
19.
DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients.
Acta Oncol
; 47(4): 709-17, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465339
20.
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Acta Oncol
; 47(4): 740-6, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465343